ArticleLeukemia2023
Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study.
Open access · hybridAbstract readLetter
In one paragraph
Article in Leukemia, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
6.0field-weighted citation impact, top 4% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 21 citations in OpenAlex.
- Genomic landscape of patients in a phase II study of zanubrutinib in ibrutinib- and/or acalabrutinib-intolerant patients with B-cell malignancies.Haematologica · 2024Trial
- Article
- ComplexInternational journal of molecular sciences · 2026Review
- Real-world safety and effectiveness of zanubrutinib vs ibrutinib in CLL: the CLL-ZANU2024 Italian cohort.Blood advances · 2026Article
- Clonal haematopoiesis in chronic lymphocytic leukaemia: Biology, inflammaging and clinical implications in the era of targeted therapy.Clinical and translational medicine · 2026Review
- TP53-aberrated CLL: is BTK inhibitor monotherapy enough?Blood advances · 2026Article
- Article
- Overall Survival Associated with Real-World Treatment Sequences in Patients with CLL/SLL in the United States.Cancers · 2025Article
- Deletion of 17p in cancers: Guilt by (p53) association.Oncogene · 2025Review
- The Role of p53 Mutations in Early and Late Response to Mitotic Aberrations.Biomolecules · 2025Review
- Detection of clinically relevant variants in theHemaSphere · 2025Article
- Insights into genetic aberrations and signalling pathway interactions in chronic lymphocytic leukemia: from pathogenesis to treatment strategies.Biomarker research · 2024Review
- Early reappearance of intraclonal proliferative subpopulations in ibrutinib-resistant chronic lymphocytic leukemia.Leukemia · 2024Article
- Non-Coding RNAs of Mitochondrial Origin: Roles in Cell Division and Implications in Cancer.International journal of molecular sciences · 2024Review
- ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia-2024 update.Leukemia · 2024Review
- Article
- NFKBIE mutations are selected by the tumor microenvironment and contribute to immune escape in chronic lymphocytic leukemia.Leukemia · 2024Article
- Low Cell Bioenergetic Metabolism Characterizes Chronic Lymphocytic Leukemia Patients with Unfavorable Genetic Factors and with a Better Response to BTK Inhibition.Current issues in molecular biology · 2024Article
- Prognosis of a Chinese patient with chronic lymphocytic leukemia who acquired a TP53 mutation following treatment with a BTK inhibitor.American journal of translational research · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 12 institutions in 2 countries.
Riccardo BombenClinical and Experimental Onco-Haematology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy. rbomben@cro.it.ORCID http://orcid.org/0000-0002-8746-9404
Francesca Maria RossiClinical and Experimental Onco-Haematology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.ORCID http://orcid.org/0000-0001-8438-1661
Filippo VitClinical and Experimental Onco-Haematology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.
Tamara BittoloClinical and Experimental Onco-Haematology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.
Antonella ZucchettoClinical and Experimental Onco-Haematology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.
Robel PapottiInternational PhD School in Clinical and Experimental Medicine, University of Modena and Reggio Emilia, Modena, Italy.
Erika TissinoClinical and Experimental Onco-Haematology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.
Federico PozzoClinical and Experimental Onco-Haematology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.ORCID http://orcid.org/0000-0002-2986-7658
Massimo DeganClinical and Experimental Onco-Haematology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.
Jerry PoleselUnit of Cancer Epidemiology, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.ORCID http://orcid.org/0000-0001-9381-1520
Pietro BulianClinical and Experimental Onco-Haematology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy.
Roberto MarascaHematology Unit, Department of Oncology and Hematology, Azienda-Ospedaliero Universitaria (AOU) of Modena, Policlinico, Modena, Italy.ORCID http://orcid.org/0000-0002-6431-6878
Gianluigi RedaDivision of Ematologia, Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico di Milano, Milano, Italy.ORCID http://orcid.org/0000-0003-4687-7089
Luca LaurentiFondazione Universitaria Policlinico A Gemelli di Roma, Roma, Italy.
Jacopo OlivieriClinica Ematologica, Centro Trapianti e Terapie Cellulari "Carlo Melzi" DISM, Azienda Ospedaliera Universitaria S. Maria Misericordia, Udine, Italy.
Annalisa ChiarenzaDivision of Hematology, Policlinico, Department of Surgery and Medical Specialties, University of Catania, Catania, Italy.
Roberta LaureanaDivision of Haematology, University of Tor Vergata, Rome, Italy.
Massimiliano PostorinoDivision of Haematology, University of Tor Vergata, Rome, Italy.
Maria Ilaria Del PrincipeDivision of Haematology, University of Tor Vergata, Rome, Italy.
Antonio CuneoHematology Section, Department of Medical Sciences, University of Ferrara, Ferrara, Italy.
Massimo GentileHematology Unit AO of Cosenza, Cosenza, Italy.
Fortunato MorabitoHematology Unit AO of Cosenza, Cosenza, Italy.
Gilberto FronzaMutagenesis and Cancer Prevention Unit, IRCCS Ospedale Policlinico San Martino, Genoa, Italy.ORCID http://orcid.org/0000-0003-3722-553X
Agostino TafuriDepartment of Clinical and Molecular Medicine and Hematology, Sant'Andrea - University Hospital - Sapienza, University of Rome, Rome, Italy.
Francesco ZajaDepartment of Medical, Surgical and Health Sciences, University of Trieste, Trieste, Italy.
Robin FoàHematology, Department of Translational and Precision Medicine, 'Sapienza' University, Rome, Italy.ORCID http://orcid.org/0000-0002-5021-3026
Francesco Di RaimondoDivision of Hematology, Policlinico, Department of Surgery and Medical Specialties, University of Catania, Catania, Italy.
Giovanni Del PoetaDivision of Haematology, University of Tor Vergata, Rome, Italy.
Valter GatteiClinical and Experimental Onco-Haematology Unit, Centro di Riferimento Oncologico di Aviano (CRO) IRCCS, Aviano, Italy. vgattei@cro.it.ORCID http://orcid.org/0000-0001-5933-9680
Centro di Riferimento Oncologico · ITUniversity of Rome Tor Vergata · ITAzienda Ospedaliera di Cosenza · ITSapienza University of Rome · ITUniversity of Catania · ITUniversity of Modena and Reggio Emilia · ITAzienda Ospedaliera S.Maria · ITFondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico · ITFondazione Roma · ITOspedale Policlinico San Martino · ITUniversity of Ferrara · ITUniversity of Trieste · IT
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Leukemia, Lymphocytic, Chronic, B-CellAdenineDrug Resistance, NeoplasmHumansPiperidinesTumor Suppressor Protein p53AdenineibrutinibPiperidinesTP53 protein, humanTumor Suppressor Protein p53
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.